Share on LinkedInShare on LinkedIn

ARTICLE · 02 JULY 2025

2025 AGA Annual Meeting Wrap-Up: Day 2

Kelley Drye & Warren LLP
Kelley Drye & Warren LLP
Contributor
Kelley Drye & Warren LLP

Kelley Drye & Warren LLP

About Kelley Drye We’re focused—in key areas of the law and on the nuances of each matter—to help...

View firm profile
Explore more from Kelley Drye & Warren LLP

In part two of this three-part series on the Attorney General Alliance (AGA) 2025 Annual Meeting, we highlight panelists' discussions on the safety and regulation of GLP-1...

United StatesConsumer Protection

In part two of this three-part series on the Attorney General Alliance (AGA) 2025 Annual Meeting, we highlight panelists' discussions on the safety and regulation of GLP-1 medications and the role of attorneys general in competitive markets. You can read part one of our series here.

Day two of the conference began with a discussion of GLP-1 drugs, such as Mounjaro, Zepbound, Ozempic, and Wegovy, a class of medications that help regulate blood sugar and control appetite, among other potential benefits. South Carolina Attorney General Alan Wilson led the conversation and explained that to capitalize on previous supply shortages and high costs, bad actors and compounding pharmacies have flooded the U.S. market with counterfeit GLP-1 drugs (generally by utilizing the "de minimis" exception for U.S. imports, which often allows the drugs to come into the country undetected). Panelists described that these counterfeit GLP-1 medications can contain contaminants or other

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from